Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

The Canada Border Services Agency (CBSA) gives tips to travellers who will be crossing the border for the Invictus Games in British Columbia from February 8-16, 2025. The Invictus Games is an ...

Nvidia Stock Is Doing Something It's Only Done Twice Before in the Past 4 Years. History Says This Will Happen Next. Super Micro’s finance chief — who is leaving as soon as the company can ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Immune checkpoint inhibitors have been the MVP of cancer drugs in recent years. Merck’s Keytruda, for example, has been used against dozens of different cancers in millions of patients ...

Keytruda market Insights: Continued dominance as a leading immunotherapy drug for multiple cancers, with expanding indications. US, NY, UNITED STATES, January 20, 2025 /EINPresswire / -- Market ...

44,097 people played the daily Crossword recently. Can you solve it faster than others?44,097 people played the daily Crossword recently. Can you solve it faster than others? Nvidia Stock Is Doing ...